Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.

Number of employees : 176 people.
Managers
Name Title Age Since
Joseph W. Turgeon President, Chief Executive Officer & Director 62 2017
Kurt A. Gustafson Chief Financial Officer & Executive Vice President 52 -
Francois Lebel, Dr. Chief Medical Officer 68 -
Lyndah K. Dreiling, Dr. Senior Vice President-Clinical Development - 2020
Thomas J. Riga Executive VP, Chief Operating & Commercial Officer 44 2017
Dolatrai M. Vyas, Dr. Independent Non-Executive Director 76 2013
Jeffrey L. Vacirca, Dr. Independent Director 51 2018
Seth H. Z. Fischer Independent Director 64 2020
Keith M. McGahan Secretary, Chief Legal Officer & SVP - 2018
Bimal R. Shah Vice President-Corporate & Business Development - 2013
Members of the board
Name Title Age Since
William L. Ashton Chairman 69 -
Joseph W. Turgeon President, Chief Executive Officer & Director 62 2017
Dolatrai M. Vyas, Dr. Independent Non-Executive Director 76 2013
Bernice R. Welles, Dr. Director 67 2018
Jeffrey L. Vacirca, Dr. Independent Director 51 2018
Seth H. Z. Fischer Independent Director 64 2020
Nora Brennan Director 51 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 163,956,341 161,470,744 98.5% 0 0.0% 98.5%
Shareholders
NameEquities%
SSgA Funds Management, Inc. 17,136,619 10.4%
Armistice Capital LLC 16,400,000 10.00%
The Vanguard Group, Inc. 10,266,411 6.26%
BlackRock Fund Advisors 6,098,874 3.72%
Macquarie Investment Management Business Trust 4,013,718 2.45%
Avoro Capital Advisor LLC 3,419,818 2.08%
Tavistock Life Sciences Co. (Investment Management) 3,333,333 2.03%
Consonance Capital Management LP 2,969,027 1.81%
Geode Capital Management LLC 2,686,533 1.64%
Broadfin Capital LLC 2,516,748 1.53%
Holdings
NameEquities%Valuation
CASI PHARMACEUTICALS, INC. (CASI) 6,886,956 4.93% 7,437,912 USD
Company contact information
Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue
Suite 240
Henderson, NV 89052

Phone : +1.702.835.6300
Fax : +1.702.260.7405
Web : http://www.sppirx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Spectrum Pharmaceuticals, Inc.